Prevalence of Oral Lesions in COVID-19 Patients

COVID-19 Clinical Trial

Official title:

Prevalence of Oral Lesions in COVID-19 Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04917549
• Other study ID #: KD/04/20
• Status: Completed
• Start date: September 2, 2020
• Est. completion date: June 10, 2021

Study information

• Verified date: April 2022
• Source: Kafrelsheikh University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Recently, a new coronavirus disease 2019 (COVID-19) has appeared and caused an unprecedented pandemic which is considered as an urgent threat to health authorities worldwide. Several symptoms are observed which are fever, cough, shortness of breath, headache, runny nose, muscle pain, fatigue, arthralgia, sputum production, conjunctivitis, diarrhea. Susceptibility, genetics, systematic diseases, population, gender, and age are crucial considerations for the onset and progression of the viral infection. The patients suffering from asthma or pulmonary deficiency are at high risk of mortality. A metallopeptidase, angiotensin-converting enzyme 2 (ACE2) is considered as the functional receptor for SARS-CoV-2 and it was isolated from a COVID-19 patient. ACE2 was recognized in type I and type II alveolar epithelial cells in both nasal and oral mucosa, in the nasopharynx, in the smooth muscle cells and endothelium of vessels in the stomach and the skin, distinctly in the basal cell layer of the epidermis extending to the basal cell layer of hair follicles, and in the basal layer of the non-keratinizing squamous epithelium. In order to study the possible routes of SARS-CoV-2 infection on the oral mucosa, we investigated whether oral lesions mainly affect the tongue mucosa due to higher ACE2-expressing cell composition and proportion more than that in other oral tissues. Moreover, appearance of oral lesions were as a result of SARS-CoV-2 infection or as a side effect of certain drugs for COVID-19 treatment was evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 124
• Est. completion date: June 10, 2021
• Est. primary completion date: June 10, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age > 18 years.

• laboratory-confirmed COVID-19 infection (reverse transcription-polymerase chain reaction, RT-PCR).

Exclusion Criteria:

• patients without a laboratory-confirmed diagnosis of COVID-19 infection.

• patients with olfactory or gustatory dysfunctions before the epidemic.

• patients with some malignant neoplasms.

• patients with neurodegenerative disorders.

Related Conditions & MeSH terms

• COVID-19

Intervention

Other:
• detection of oral lesions
oral lesions in patient diagnosed with COVID-19

Locations

Country	Name	City	State
Egypt	Dalia Rasheed Issa	Kafr Ash Shaykh	Kafr El-sheikh

Sponsors (1)

Lead Sponsor	Collaborator
Kafrelsheikh University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	site of mucosa affected by oral lesions	Number and site of oral lesions that affect the oral cavity	1 month
Secondary	treatment of the patients	the correlation between the medications and the oral lesions	1 month